It's one of the year's most-talked-about cancer stories, but it's not about the disease itself.
Instead, it's about the science behind it.
In the latest issue of CURE, the journal for the American Cancer Society, researchers report on the "unprecedented" progress being made in the treatment of bladder cancer.
The FDA has approved two new treatments: Anktiva, which uses the BCG vaccine to treat non-muscle-invasive bladder cancer, and Opdivo, which uses the antibodynivolumab to treat unresectable or metastatic urothelial carcinoma.
The bladder cancer treatment "hasrevolutionized the way we're looking at bladder cancer," one expert tells CURE, while another says that chemotherapy has long been the standard of care for this type of cancer.
In a clinical trial, patients who received Opdivo plus cisplatin and gemcitabine lived longer than those who received the chemotherapy drugs cisplatin and gemcitabine, reports the New York Times, which notes that this is the first time an FDA-approved treatment has been shown to extend the lives of people with this type of cancer.
(Click to read about another "groundbreaking" cancer study
Read the Entire Article
A customized collection of news from foundations from around the Web.
Several British colleges and universities have embraced social entrepreneurship in their curriculum. Pathik Pathak at Southampton have introduced n interdisciplinary module in Social Enterprise, which is open to students of all year groups and across all disciplines.